Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

H Lee Moffitt Cancer Center and Research Institute Hospital Inc

Neither a doctor nor a teaching hospital

Research payments

$5,657,469

370 payments

Through program year 2025, H Lee Moffitt Cancer Center and Research Institute Hospital Inc is reported as receiving $5,657,469 in research payments, across 370 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $5,265,664 230
2024 Research $86,108 22
2023 Research $52,858 24
2022 Research $108,722 67
2021 Research $5,095 3
2020 Research $11,219 11
2019 Research $127,802 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $4,375,445 42 payments
  2. Gilead Sciences, Inc. $517,957 5 payments
  3. Taiho Oncology, Inc. $253,543 44 payments
  4. Geron Corporation $219,971 171 payments
  5. Daiichi Sankyo Inc. $103,968 12 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $53,934 22 payments
  7. Otsuka Pharmaceutical Co., Ltd. $37,335 15 payments
  8. Genmab U.S., Inc. $36,691 10 payments
  9. Eisai Inc. $27,653 30 payments
  10. Servier BioInnovation $13,157 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. 0000000000000000000000000000000000000000000000000000000000000000215126 $4,350,707 31 payments
  2. IMMU132-2020-051 Phase I/II Study of Stereotactic Radiation and Sacituzumab with Nivolumab in the Management of Metastatic Triple Negative and HER2+ Breast Cancer with Brain Metastases $515,516 1 payment
  3. A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors. $166,300 17 payments
  4. A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment $111,368 120 payments
  5. A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor $108,603 51 payments
  6. Study name not reported $103,968 12 payments
  7. A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability and Pharmacokinetic Study of TAS3681 in Patients With Metastatic Castration Resistant Prostate Cancer $87,243 27 payments
  8. A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. $36,691 10 payments
  9. BAY73-4506, phase I, HCC 1st line combination PD1inh $34,019 14 payments
  10. A Randomized, Open-Label, Phase 1-2 Study of Astx727 Low Dose Astx727 LD Extended Schedule in Subjects With Lower Risk Ipss Low Or Intermediate-1 Myelodysplastic Syndromes MDS $23,834 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record